Factor Xa inhibitors (apixaban, rivoraxaban) and direct thrombin inhibition (dabigitran), serve as newer therapeutic targets offering comparable efficacy to warfarin for both the reduction of stroke in atrial fibrillation and rates of recurrent venous thromboembolism in deep venous thrombosis [38,39,40,41,42]. Here, F10 is linked to stroke disorder.